NCT06936215View on ClinicalTrials.gov

Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Diffuse Cutaneous Systemic Sclerosis

Interventions

DRUG

tab baricitinib 4 mg daily

Group A participants will be given tab. Baricitinib 4 mg daily

DRUG

tab methotrexate 25 mg weekly with folic acid 5 mg weekly

group A participants will be given tab. baricitinib 4 mg daily and group B participants will be given tab. methotrexate 25 mg weekly with folic acid 5 mg weekly

Trial Locations (1)

Unknown

RECRUITING

BSMMU, Dhaka

All Listed Sponsors

lead

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER